Skip to main content
. 2020 Dec 2;15(12):e0242559. doi: 10.1371/journal.pone.0242559

Fig 5.

Fig 5

Comparison of total B and plasma B cells between R group and NR group during PEG-IFN treatment (A) Total B cells in age-, sex-, and HBsAg level at baseline -matched patients: comparison between IHCs who achieved seroconversion at 24 weeks of treatment (n = 7) and the patients who failed at 24 weeks of treatment (n = 7). (B) Plasma B cells in age-, sex-, and HBsAg level at baseline-matched patients: Comparison between IHCs who achieved HBsAg seroconversion at 24 weeks of treatment (n = 7) and the patients who failed at 24 weeks of treatment (n = 7).